Long-acting growth hormone subcutaneous injection (somatrogon-ghla): product introduction and marketing details

Long-acting subcutaneous injection of growth hormone (Somatrogon-ghla) is an innovative drug specifically designed to treat growth disorders in children caused by insufficient secretion of endogenous growth hormone. The drug offers new treatment hope for children who face growth challenges due to growth hormone deficiency by mimicking the body's naturally produced growth hormone.

As a long-acting formulation, Somatrogon-ghla is unique in that it can significantly reduce the frequency of injections for patients, switching from traditional daily injections to once a week. This improvement not only improves patient medication compliance, but also reduces the inconvenience and pain caused by frequent injections. The drug is administered by subcutaneous injection. The injection site can be selected on the abdomen, thigh, buttocks or upper arm, and needs to be rotated weekly to ensure uniform absorption of the drug and reduce local adverse reactions.

During the development process,Somatrogon-ghla has undergone rigorous clinical trials and regulatory approvals. It was first approved for medical use in Australia in 2021, followed by the European Union in 2022. In 2023, the U.S. Food and Drug Administration (FDA) also officially approved Somatrogon-ghla for the treatment of growth hormone deficiency in children. These international approvals mark broad recognition of Somatrogon-ghla's efficacy and safety.

The manufacturer of Somatrogon-ghla is Pfizer of the United States. The company ensures the high quality and reliability of the drug with its excellent research and development capabilities and strict quality control system. At present, this drug is not on the market in China, and domestic patients are temporarily unable to obtain this drug from China. In clinical application,Somatrogon-ghla has shown significant efficacy, helping patients achieve normal height growth and improve their quality of life.

With the gradual promotion and application of Somatrogon-ghla around the world, more and more patients with growth hormone deficiency will benefit from this innovative drug. It not only provides patients with new treatment options, but also provides doctors and medical workers with more convenient and effective treatment methods.

Reference: https://www.drugs.com/monograph/somatrogon-ghla.html